Bafna Pharmaceuticals (BAFNAPH) Q3 2025 earnings summary

Executive summary

• Reported total income of ₹3,337.72 lakhs for Q3 FY25, up from ₹2,942.13 lakhs in Q3 FY24, and ₹10,851.42 lakhs for the nine months ended Dec 2024.

• Net profit for Q3 FY25 stood at ₹94.77 lakhs, compared to a net loss of ₹294.24 lakhs in Q3 FY24.

• Board approved sale of Madhavaram manufacturing unit, classified as 'Assets Held for Sale.'

Financial highlights

• Revenue from operations for Q3 FY25 was ₹3,318.76 lakhs, up from ₹2,844.22 lakhs in Q3 FY24.

• Total expenses for Q3 FY25 were ₹3,241.75 lakhs, compared to ₹3,236.37 lakhs in Q3 FY24.

• Earnings per share (EPS) for Q3 FY25 was ₹0.40, versus negative ₹1.24 in Q3 FY24.

• Exceptional item in Q3 FY25: derecognition of inventory worth ₹1.20 lakhs.

Outlook and guidance

• Management is taking initiatives to conclude the sale of the Madhavaram unit and regularize statutory compliances, including minimum public shareholding.